Skip to content
Screener

Sionna Therapeutics SION Business Segments — Fees paid to licensors

Similar metrics at other companies

Bicara Therapeutics logo
BCAXReportable Segment — Professional fees
$3.56M+137%
BitGo Holdings logo
BTGOReportable Segment — Staking fees
$41.44M-67.6%
SLM logo
SLMReportable Segment — Professional fees
$28.77M+41.6%
Fulton Financial logo
FULTReportable Segment — Professional fees
$1.37M-49.4%
LPR
LPROReportable Segment — Professional fees
$2.51M+9.2%
comScore logo
SCORReportable Segment — Professional fees
$5.59M+14.4%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Cash & equivalents$64.3M-23.2%
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$203.46M-77.0%
Enterprise value$147.55M-82.7%

Returns & leverage

See full
Return on equity-26.7%
Debt / equity0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by Sionna Therapeutics in its filing.

Tagged under the XBRL concept sionna:FeesPaidToLicensors.

The source filing: Sionna Therapeutics’s 10-K, filed March 2, 2026.

Filed
Mar 2, 2026, 7:19 AM EST
Fiscal year
FY2025
Accession
0001628280-26-012996
Line itemYear Ended December 31, 2025Year Ended December 31, 2024
Research and development expenses:
External research and development expenses(1)$43,535$31,873
Fees paid to licensors(2)235,525
Personnel-related expenses, excluding stock-based compensation10,5537,628
Facility and information technology allocated expenses1,8261,838
General and administrative expenses:
Personnel-related expenses, excluding stock-based compensation10,9475,634
General corporate and facility expenses(3)8,4014,222

Item 8. Financial Statements and Supplementary DataF-

FAQ

What is Sionna Therapeutics's business segments — fees paid to licensors?
Sionna Therapeutics (SION) reported business segments — fees paid to licensors of $5.75K in Q4 2025.
How has Sionna Therapeutics's business segments — fees paid to licensors changed year-over-year?
Sionna Therapeutics's business segments — fees paid to licensors decreased by 99.6% year-over-year, from $1.38M to $5.75K.
What does business segments — fees paid to licensors mean?
Tracks the cash payments made to third-party licensors for the rights to use intellectual property, patents, or proprietary technology within a business segment. These fees are critical for companies relying on in-licensed assets to drive their research and development programs. Monitoring these payments helps investors understand the long-term cost structure and royalty obligations associated with the segment's technology portfolio.

Ask your AI about Sionna Therapeutics's business segments — fees paid to licensors.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude